Literature DB >> 28693744

Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants.

Jeffrey M Ashburner1, Daniel E Singer2, Steven A Lubitz3, Leila H Borowsky4, Steven J Atlas2.   

Abstract

Atrial fibrillation (AF) and the decision to anticoagulate is a common problem faced by primary care physicians. Oral anticoagulation (OAC) is underused, despite its clear benefits with regard to stroke prevention. We examined OAC usage between 2010 and 2015, following the introduction of direct oral anticoagulants (DOACs) and specifically assessed whether more patients were anticoagulated over time. The study cohort included adult patients aged 18 and older with AF cared for in an 18-practice primary care network between 2010 and 2015. AF status was assigned each calendar year using a validated electronic health record algorithm. We examined OAC usage over time in all patients with AF, and in patients at high risk of stroke (CHA2DS2-VASc ≥ 2). The proportion of the population with AF increased over time (2010: 4,920 patients [3.5%], 2015: 6,452 patients [4.0%]). There was no increase in the proportion of patients prescribed any OAC treatment from 2010 (57.0%) to 2015 (57.4%) (p = 0.41). Similarly, in patients at high risk of stroke, the proportion anticoagulated did not increase over time (2010: 61.1%, 2015: 61.7%, p = 0.51). Over the study period, DOAC usage increased from 0.31% of all patients with AF in 2010 to 18.3% in 2015 (p < 0.001). Patients prescribed DOACs were younger, with lower risk of stroke. In conclusion, this study showed an increasing proportion of patients with AF over time in a primary care network. The use of DOACs increased over time; however, the proportion of patients treated with OAC did not increase over time.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28693744     DOI: 10.1016/j.amjcard.2017.05.055

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.

Authors:  Junya Zhu; G Caleb Alexander; Saman Nazarian; Jodi B Segal; Albert W Wu
Journal:  Pharmacotherapy       Date:  2018-07-26       Impact factor: 4.705

2.  Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trial.

Authors:  Jeffrey M Ashburner; Steven J Atlas; David D McManus; Yuchiao Chang; Ana T Trisini Lipsanopoulos; Leila H Borowsky; Wyliena Guan; Wei He; Patrick T Ellinor; Daniel E Singer; Steven A Lubitz
Journal:  Am Heart J       Date:  2019-06-22       Impact factor: 4.749

3.  Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation.

Authors:  Shirley V Wang; James R Rogers; Yinzhu Jin; David DeiCicchi; Sara Dejene; Jean M Connors; David W Bates; Robert J Glynn; Michael A Fischer
Journal:  BMJ Qual Saf       Date:  2019-06-26       Impact factor: 7.035

4.  Safety of laparoscopic inguinal hernia repair in the setting of antithrombotic therapy.

Authors:  Jeremy A Balch; Dan Neal; Cristina Crippen; Crystal N Johnson-Mann; Thomas E Read; Tyler J Loftus; Mazen R Al-Mansour
Journal:  Surg Endosc       Date:  2022-06-08       Impact factor: 4.584

5.  Prescribing of anticoagulation for atrial fibrillation in primary care.

Authors:  Kathryn A Martinez; Mark H Eckman; Matthew A Pappas; Michael B Rothberg
Journal:  J Thromb Thrombolysis       Date:  2022-04-21       Impact factor: 2.300

6.  Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial.

Authors:  Steven A Lubitz; Steven J Atlas; Jeffrey M Ashburner; Ana T Trisini Lipsanopoulos; Leila H Borowsky; Wyliena Guan; Shaan Khurshid; Patrick T Ellinor; Yuchiao Chang; David D McManus; Daniel E Singer
Journal:  Circulation       Date:  2022-03-02       Impact factor: 29.690

7.  Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort.

Authors:  Kristi M Swanson; Ye Zhu; Ricardo L Rojas; Jennifer L St Sauver; Suzette J Bielinski; Debra J Jacobsen; Sue L Visscher; Liewei Wang; Richard Weinshilboum; Bijan J Borah
Journal:  PLoS One       Date:  2020-05-19       Impact factor: 3.240

8.  Idarucizumab for a traumatic head injury patient taking dabigatran.

Authors:  Shuhei Maruyama; Koichi Hayakawa; Shuji Kanayama; Hiromu Iwamura; Daiki Wada; Fukuki Saito; Yasushi Nakamori; Yasuyuki Kuwagata
Journal:  Int J Emerg Med       Date:  2018-10-03

9.  Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities).

Authors:  Liping Mou; Faye L Norby; Lin Y Chen; Wesley T O'Neal; Tené T Lewis; Laura R Loehr; Elsayed Z Soliman; Alvaro Alonso
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-07

10.  Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial.

Authors:  Jeffrey M Ashburner; Steven J Atlas; Shaan Khurshid; Lu-Chen Weng; Olivia L Hulme; Yuchiao Chang; Daniel E Singer; Patrick T Ellinor; Steven A Lubitz
Journal:  J Gen Intern Med       Date:  2018-08-03       Impact factor: 6.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.